Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
2. 2-(2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
3. Abt 888
4. Abt-888
5. Abt888
1. 912444-00-9
2. Abt-888
3. Abt 888
4. Abt-888 (veliparib)
5. Veliparib Free Base
6. Abt888
7. (r)-2-(2-methylpyrrolidin-2-yl)-1h-benzo[d]imidazole-4-carboxamide
8. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide
9. 2-[(2r)-2-methyl-2-pyrrolidinyl]-1h-benzimidazole-7-carboxamide
10. Chebi:62880
11. 2-[(r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide
12. Parp-1 Inhibitor Abt-888
13. 912444-00-9 (free Base)
14. 01o4k0631n
15. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benimidazole-4-
16. (2r)-2-(7-carbamoyl-1h-benzimidazol-2-yl)-2-methylpyrrolidinium
17. 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
18. Veliparib (abt-888)
19. (r)-2-(2-methylpyrrolidin-2-yl)-1h-benimidazole-4-carboxamide (veliparib)
20. 2-((2r)-2-methyl-2-pyrrolidinyl)-1h-benzimidazole-7-carboxamide
21. 2-((2r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
22. Nsc-737664
23. Veliparib [usan:inn]
24. Mfcd16661059
25. Unii-01o4k0631n
26. 78p
27. Veliparib [inn]
28. Veliparib [jan]
29. Veliparib [usan]
30. Abt888 (free Base)
31. (r)-2-(2-methylpyrrolidin-2-yl)-1h-benzo[d]imidazole-7-carboxamide
32. Veliparib [who-dd]
33. Benzimidazole Carboxamide, 3a
34. Mls006010184
35. Veliparib (jan/usan/inn)
36. Schembl422318
37. Chembl506871
38. Gtpl7417
39. Bdbm27135
40. Abt-695
41. Dtxsid90238456
42. Ex-a001
43. Bdbm209932
44. Veliparib (abt-888 Hydrochloride)
45. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-1,3-benzodiazole-4-carboxamide
46. Nsc737664
47. Nsc752840
48. S1004
49. Zinc84610155
50. Akos015951440
51. Akos017343746
52. Ccg-264771
53. Cs-0076
54. Db07232
55. Ex-7209
56. Nsc 737664
57. Nsc-752840
58. Sb16480
59. Ncgc00250404-01
60. Ncgc00250404-15
61. Ac-23330
62. As-19397
63. Hy-10129
64. Smr004701290
65. Abt-888 (veliparib, Nsc 737664)
66. A24888
67. D09692
68. A 861695
69. A-861695
70. J-505211
71. Q7919041
72. Brd-k87142802-001-02-7
73. 1h-benzimidazole-4-carboxamide, 2-((2r)-2-methyl-2-pyrrolidinyl)-
74. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benimidazole-4-carboxamide
75. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-7-carboxamide
76. 2-[(r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide;
77. 1h-benzimidazole-7-carboxamide, 2-((2r)-2-methyl-2-pyrrolidinyl)-
| Molecular Weight | 244.29 g/mol |
|---|---|
| Molecular Formula | C13H16N4O |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 244.13241115 g/mol |
| Monoisotopic Mass | 244.13241115 g/mol |
| Topological Polar Surface Area | 83.8 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 348 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of fallopian tube cancer , Treatment of ovarian cancer , Treatment of peritoneal carcinoma
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
Treatment of breast cancer
Treatment of high-grade glioma
Poly(ADP-ribose) Polymerase Inhibitors
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XK - Poly (adp-ribose) polymerase (parp) inhibitors
L01XK05 - Veliparib
ABOUT THIS PAGE
A Veliparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Veliparib, including repackagers and relabelers. The FDA regulates Veliparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Veliparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Veliparib supplier is an individual or a company that provides Veliparib active pharmaceutical ingredient (API) or Veliparib finished formulations upon request. The Veliparib suppliers may include Veliparib API manufacturers, exporters, distributors and traders.
Veliparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Veliparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Veliparib GMP manufacturer or Veliparib GMP API supplier for your needs.
A Veliparib CoA (Certificate of Analysis) is a formal document that attests to Veliparib's compliance with Veliparib specifications and serves as a tool for batch-level quality control.
Veliparib CoA mostly includes findings from lab analyses of a specific batch. For each Veliparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Veliparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Veliparib EP), Veliparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Veliparib USP).
LOOKING FOR A SUPPLIER?
